Gemini Therapeutics (NASDAQ:GMTX) Trading 4.6% Higher – Should You Buy?

Gemini Therapeutics, Inc. (NASDAQ:GMTX)’s stock price was up 4.6% during trading on Thursday . The stock traded as high as $81.18 and last traded at $80.94. Approximately 436,307 shares were traded during trading, an increase of 130% from the average daily volume of 189,291 shares. The stock had previously closed at $77.36.

Gemini Therapeutics Trading Up 4.6%

The firm has a market cap of $3.51 billion, a P/E ratio of -80.94 and a beta of -0.12. The company’s 50-day moving average is $86.98 and its two-hundred day moving average is $71.33.

Gemini Therapeutics Company Profile

Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.